Akums gets DCGI nod for triple combination diabetes medication
Jan 17 (Reuters) - Merck & Co (MRK.N) has discovered how its blockbuster diabetes drugs have become contaminated with a potential carcinogen and believes it can resolve the problem by the end of the year, Bloomberg News reported on Tuesday.
Chief Executive Officer of Pharmaceuticals and Medical devices Bureau of India (PMBI) Ravi Dadhich launched Sitagliptin, a new variant of medicines for diabetes, recently, at affordable prices for all under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana. PMBI included new variants of medicines Sitagliptin and its combination in its all Jan Aushdhi Kendras.
REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the amendment and extension of its agreement with Merck, known as MSD outside the United States and Canada, to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin, the active pharmaceutical ingredient (API) in Merck’s JANUVIA® and one of the active ingredients in Merck’s JANUMET®.